Metraipolis › archive › dc_b72fa4019e72

Efficacy and Safety of Pirfenidone for Mitigation of Interstitial Lung Abnormalities in COVID-19 Patients: A Meta-Analysis — Europe PMC PMID:41522210

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41522210
DOI
10.1155/carj/8812779
License (as archived)
solo-consultazione
Archived
2026-11-06T22:20:39.064Z
SHA-256 of the archived text
13b3f31ddfc94153495497e8f35ec9d938033e64b315f8a2dd93bc3a5f5e5697
Stable URL of this page
https://metraipolis.com/documento/dc_b72fa4019e72

How to cite

Efficacy and Safety of Pirfenidone for Mitigation of Interstitial Lung Abnormalities in COVID-19 Patients: A Meta-Analysis — Europe PMC PMID:41522210 — Europe PMC (en), https://europepmc.org/article/MED/41522210 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_b72fa4019e72 (Metraipolis archive dc_b72fa4019e72, sha256 13b3f31ddfc94153495497e8f35ec9d938033e64b315f8a2dd93bc3a5f5e5697)
BibTeX
@misc{dcb72fa4019e72,
  title = {Efficacy and Safety of Pirfenidone for Mitigation of Interstitial Lung Abnormalities in COVID-19 Patients: A Meta-Analysis — Europe PMC PMID:41522210},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41522210},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_b72fa4019e72; sha256 13b3f31ddfc94153495497e8f35ec9d938033e64b315f8a2dd93bc3a5f5e5697},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41522210. Agents can read the archived copy with the MCP tool read_document.